Clonal Selection

Clonal selection is the process by which a single damaged cell, one that has gained a survival or growth advantage from a mutation, multiplies and outcompetes its neighbors, eventually giving rise to a population of identical descendant cells. In cancer, this is how a tumor grows from one altered cell into a mass of related cells, and how that tumor can later evolve resistance to treatment as new mutations are 'selected for' over time.

Origin

The term comes from the Latin root for 'twig' or 'cutting' (clone) and the Darwinian concept of natural selection. It was first applied to biology by Frank Macfarlane Burnet in 1957 to describe how immune cells are selected, and was later adopted by cancer researchers, most notably Peter Nowell in his 1976 paper proposing that tumors evolve through successive rounds of clonal selection.

Significance in Asbestos Context

For mesothelioma and asbestos-related lung cancer, clonal selection helps explain the long latency between exposure and diagnosis, often 20 to 50 years. Asbestos fibers cause repeated DNA damage in mesothelial or lung cells, and over decades, a single cell that acquires the right combination of mutations (often involving BAP1, CDKN2A, or NF2 in mesothelioma) can be 'selected' to expand into a tumor. This concept matters in your case because it supports the medical consensus that even decades-old exposures can be the cause of disease diagnosed today, and it underlies why mesothelioma tumors often become resistant to chemotherapy: surviving cells from an initial treatment are 'selected' and regrow as a more aggressive clone. Your oncologist may reference clonal evolution when discussing why a treatment that worked initially has stopped working, or when recommending genomic testing of the tumor.

Example Sentence

The pathologist explained that clonal selection over decades after his shipyard exposure likely allowed a single damaged pleural cell to develop into the mesothelioma now visible on imaging.

Related Terms

Latency Period, BAP1, Tumor Heterogeneity, Carcinogenesis, Somatic Mutation, Chemoresistance

Notes

• If your tumor has been biopsied, ask whether molecular or genomic testing (such as next-generation sequencing) has been done. Results can identify mutations that guide treatment and clinical trial eligibility.
• Preserve all pathology reports and molecular testing results; these documents support the medical explanation of how an old exposure caused a present-day tumor.
• If a treatment stops working, ask your oncologist whether a repeat biopsy or liquid biopsy could identify new mutations from clonal evolution that might respond to a different therapy.
• When documenting your exposure history for a legal claim, note that the long gap between exposure and diagnosis is medically expected and consistent with how clonal selection drives mesothelioma development.